179 related articles for article (PubMed ID: 34440904)
1. Development of an Imaging Technique for Boron Neutron Capture Therapy.
Fukumitsu N; Matsumoto Y
Cells; 2021 Aug; 10(8):. PubMed ID: 34440904
[TBL] [Abstract][Full Text] [Related]
2. 4-Borono-2-
Ishiwata K
Ann Nucl Med; 2019 Apr; 33(4):223-236. PubMed ID: 30820862
[TBL] [Abstract][Full Text] [Related]
3. Non-invasive estimation of
Yoshimoto M; Honda N; Kurihara H; Hiroi K; Nakamura S; Ito M; Shikano N; Itami J; Fujii H
Cancer Sci; 2018 May; 109(5):1617-1626. PubMed ID: 29498142
[TBL] [Abstract][Full Text] [Related]
4. Similar T/N ratio between
Lin YC; Chou FI; Yang BH; Chang CW; Chen YW; Hwang JJ
Ann Nucl Med; 2020 Jan; 34(1):58-64. PubMed ID: 31650410
[TBL] [Abstract][Full Text] [Related]
5. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma.
Nariai T; Ishiwata K; Kimura Y; Inaji M; Momose T; Yamamoto T; Matsumura A; Ishii K; Ohno K
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S348-50. PubMed ID: 19375930
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the pharmacokinetics between L-BPA and L-FBPA using the same administration dose and protocol: a validation study for the theranostic approach using [
Watanabe T; Hattori Y; Ohta Y; Ishimura M; Nakagawa Y; Sanada Y; Tanaka H; Fukutani S; Masunaga SI; Hiraoka M; Ono K; Suzuki M; Kirihata M
BMC Cancer; 2016 Nov; 16(1):859. PubMed ID: 27821116
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of 4-borono-2-18F-fluoro-L-phenylalanine-fructose as a probe for boron neutron capture therapy in a glioma-bearing rat model.
Wang HE; Liao AH; Deng WP; Chang PF; Chen JC; Chen FD; Liu RS; Lee JS; Hwang JJ
J Nucl Med; 2004 Feb; 45(2):302-8. PubMed ID: 14960653
[TBL] [Abstract][Full Text] [Related]
8. Assessment of
Shimosegawa E; Isohashi K; Naka S; Horitsugi G; Hatazawa J
Ann Nucl Med; 2016 Dec; 30(10):749-755. PubMed ID: 27586407
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the total distribution volume of
Romanov V; Isohashi K; Alobthani G; Beshr R; Horitsugi G; Kanai Y; Naka S; Watabe T; Shimosegawa E; Hatazawa J
Ann Nucl Med; 2020 Mar; 34(3):155-162. PubMed ID: 31808134
[TBL] [Abstract][Full Text] [Related]
10. On the applicability of [
Grunewald C; Sauberer M; Filip T; Wanek T; Stanek J; Mairinger S; Rollet S; Kudejova P; Langer O; Schütz C; Blaickner M; Kuntner C
Nucl Med Biol; 2017 Jan; 44():83-89. PubMed ID: 27837726
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption.
Hsieh CH; Chen YF; Chen FD; Hwang JJ; Chen JC; Liu RS; Kai JJ; Chang CW; Wang HE
J Nucl Med; 2005 Nov; 46(11):1858-65. PubMed ID: 16269600
[TBL] [Abstract][Full Text] [Related]
12. Uptake of 4-borono-2-[18F]fluoro-L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET.
Havu-Aurén K; Kiiski J; Lehtiö K; Eskola O; Kulvik M; Vuorinen V; Oikonen V; Vähätalo J; Jääskeläinen J; Minn H
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):87-94. PubMed ID: 16896669
[TBL] [Abstract][Full Text] [Related]
13. FBPA PET in boron neutron capture therapy for cancer: prediction of (10)B concentration in the tumor and normal tissue in a rat xenograft model.
Hanaoka K; Watabe T; Naka S; Kanai Y; Ikeda H; Horitsugi G; Kato H; Isohashi K; Shimosegawa E; Hatazawa J
EJNMMI Res; 2014 Dec; 4(1):70. PubMed ID: 25621196
[TBL] [Abstract][Full Text] [Related]
14. Reliable radiosynthesis of 4-[
Ishiwata K; Ebinuma R; Watanabe C; Hayashi K; Toyohara J
Ann Nucl Med; 2018 Aug; 32(7):463-473. PubMed ID: 29869193
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography and [18F]BPA: a perspective application to assess tumour extraction of boron in BNCT.
Menichetti L; Cionini L; Sauerwein WA; Altieri S; Solin O; Minn H; Salvadori PA
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S351-4. PubMed ID: 19410471
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the image-derived radioactivity and blood-sample radioactivity for estimating the clinical indicators of the efficacy of boron neutron capture therapy (BNCT): 4-borono-2-
Isohashi K; Shimosegawa E; Naka S; Kanai Y; Horitsugi G; Mochida I; Matsunaga K; Watabe T; Kato H; Tatsumi M; Hatazawa J
EJNMMI Res; 2016 Dec; 6(1):75. PubMed ID: 27757932
[TBL] [Abstract][Full Text] [Related]
17. Predominant contribution of L-type amino acid transporter to 4-borono-2-(18)F-fluoro-phenylalanine uptake in human glioblastoma cells.
Yoshimoto M; Kurihara H; Honda N; Kawai K; Ohe K; Fujii H; Itami J; Arai Y
Nucl Med Biol; 2013 Jul; 40(5):625-9. PubMed ID: 23557719
[TBL] [Abstract][Full Text] [Related]
18. A Metabolically Stable Boron-Derived Tyrosine Serves as a Theranostic Agent for Positron Emission Tomography Guided Boron Neutron Capture Therapy.
Li J; Shi Y; Zhang Z; Liu H; Lang L; Liu T; Chen X; Liu Z
Bioconjug Chem; 2019 Nov; 30(11):2870-2878. PubMed ID: 31593447
[TBL] [Abstract][Full Text] [Related]
19. Macro- and microdistributions of boron drug for boron neutron capture therapy in an animal model.
Lin YC; Hwang JJ; Wang SJ; Yang BH; Chang CW; Hsiao MC; Chou FI
Anticancer Res; 2012 Jul; 32(7):2657-64. PubMed ID: 22753723
[TBL] [Abstract][Full Text] [Related]
20. A unique in vivo assessment of 4-[10B]borono-L-phenylalanine in tumour tissues for boron neutron capture therapy of malignant melanomas using positron emission tomography and 4-borono-2-[18F]fluoro-L-phenylalanine.
Ishiwata K; Shiono M; Kubota K; Yoshino K; Hatazawa J; Ido T; Honda C; Ichihashi M; Mishima Y
Melanoma Res; 1992 Sep; 2(3):171-9. PubMed ID: 1450671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
